Review Article | By M Valgimigli , R Mehran, SIDNEY Collaboration et al.
OBJECTIVES - The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stents. BACKGROUND - The role of abbreviated DAPT followed by an oral P2Y12 inhibitor after PCI remains uncertain. METHODS - Two randomized trials, including 14,628 patients undergoing PCI...
Clinical Trial | By S-J Lee, JY Cho, TICO Investigators et al.
OBJECTIVES - The aim of this study was to assess whether the effects of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) are consistent among patients presenting with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction, and unstable angina treated with drug-eluting stents. BACKGROUND - Ticagrelor monotherapy after short-term ...
Clinical Trial | By Z Ge, JJ Zhang, SL Chen et al.
BACKGROUND - Current guidelines recommend administering dual antiplatelet therapy (DAPT) for 12 months to patients with acute coronary syndromes (ACS) and without contraindications after drug-eluting stent (DES) implantation. A recent study reported that 3 months of DAPT followed by ticagrelor monotherapy is effective and safe in ACS patients undergoing DES implantation compared with the standard duration of DAPT. Ho...
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
Original Research | By DJA Jenkins, M Dehghan, PURE Study Investigators et al.
BACKGROUD - Most data regarding the association between the glycemic index and cardiovascular disease come from high-income Western populations, with little information from non-Western countries with low or middle incomes. To fill this gap, data are needed from a large, geographically diverse population. METHODS - This analysis includes 137,851 participants between the ages of 35 and 70 years living on five cont...
Original Research | By H Ota, H Omori, M Kawasaki et al.
AIMS - This study aimed to determine the effects of a proprotein convertase subtilisin-kexin type 9 inhibitor (PCSK9i) on coronary plaque volume and lipid components in patients with a history of coronary artery disease (CAD). METHODS AND RESULTS - This prospective, open-label, single-centre study analysed non-culprit coronary segments using near-infrared spectroscopy-intravascular ultr...
Original Research | By C Genz, RC Braun-Dullaeus.
BACKGROUND - Approximately 18% of patients with atrial fibrillation undergo a percutaneous coronary intervention (PCI) to treat coronary heart disease. Pharmacological anticoagulation in patients with atrial fibrillation and PCI involves a trade-off of potential ischemic and hemorrhagic complications. METHODS - This review is based on pertinent publications that were retrieved by a selective li...
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk
Clinical Trial | By MB Leon , MJ Mack, and the PARTNER 3 Investigators.
BACKGROUND - In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year. OBJECTIVES ...
Clinical Trial | By SJ. Baron, EA Magnuson, the PARTNER 3 Investigators et al.